Milestone Pharmaceuticals Inc. (MIST) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts MIST Hot Sheet
Join SI Premium – FREE
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $559 million.
For earnings history and earnings-related data on Milestone Pharmaceuticals Inc. (MIST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zuckerberg: Meta has reached AI ‘frontier,’ rejects calls for slowdown
- Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c
- Fed’s Hammack calls for quick move to restrictive policy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
